DE69432517D1 - Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit - Google Patents
Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeitInfo
- Publication number
- DE69432517D1 DE69432517D1 DE69432517T DE69432517T DE69432517D1 DE 69432517 D1 DE69432517 D1 DE 69432517D1 DE 69432517 T DE69432517 T DE 69432517T DE 69432517 T DE69432517 T DE 69432517T DE 69432517 D1 DE69432517 D1 DE 69432517D1
- Authority
- DE
- Germany
- Prior art keywords
- effectiveness
- vitability
- survivality
- predicting
- tumor treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 230000003833 cell viability Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8440293A | 1993-06-29 | 1993-06-29 | |
| PCT/US1994/007476 WO1995001455A1 (en) | 1993-06-29 | 1994-06-29 | NATIVE-STATE METHOD AND SYSTEM FOR DETERMINING VIABILITY AND PROLIFERATIVE CAPACITY OF TISSUES $i(IN VITRO) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69432517D1 true DE69432517D1 (de) | 2003-05-22 |
| DE69432517T2 DE69432517T2 (de) | 2003-12-24 |
Family
ID=22184744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69432517T Expired - Lifetime DE69432517T2 (de) | 1993-06-29 | 1994-06-29 | Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0714448B1 (de) |
| AT (1) | ATE237697T1 (de) |
| AU (1) | AU7357894A (de) |
| DE (1) | DE69432517T2 (de) |
| WO (1) | WO1995001455A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004044177A2 (en) * | 2002-11-12 | 2004-05-27 | Anticancer, Inc. | Expression profiling based on histocultures |
| KR20230128096A (ko) * | 2020-12-31 | 2023-09-01 | 엘레파스 바이오사이언스 코퍼레이션 | 조직에 대한 약물 또는 기타 제제의 효과를 결정하기위한 생체외 시스템 및 방법 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990011371A1 (en) * | 1989-03-20 | 1990-10-04 | Anticancer Inc. | NATIVE-STATE METHOD AND SYSTEM FOR DETERMINING VIABILITY AND PROLIFERATIVE CAPACITY OF TISSUES $i(IN VITRO) |
-
1994
- 1994-06-29 EP EP94922483A patent/EP0714448B1/de not_active Expired - Lifetime
- 1994-06-29 DE DE69432517T patent/DE69432517T2/de not_active Expired - Lifetime
- 1994-06-29 WO PCT/US1994/007476 patent/WO1995001455A1/en active IP Right Grant
- 1994-06-29 AT AT94922483T patent/ATE237697T1/de not_active IP Right Cessation
- 1994-06-29 AU AU73578/94A patent/AU7357894A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995001455A1 (en) | 1995-01-12 |
| AU7357894A (en) | 1995-01-24 |
| EP0714448B1 (de) | 2003-04-16 |
| EP0714448A4 (de) | 1998-05-20 |
| ATE237697T1 (de) | 2003-05-15 |
| EP0714448A1 (de) | 1996-06-05 |
| DE69432517T2 (de) | 2003-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
| DE69635671D1 (de) | Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren | |
| DE60037394D1 (de) | VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE | |
| DE60036025D1 (de) | Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten | |
| ES2133807T3 (es) | Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas. | |
| DE69828408D1 (de) | Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung | |
| UA74325C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ р38, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇХ МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ ЗА ЇХ ДОПОМОГОЮ | |
| DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| DE3880118D1 (de) | Verwendung eines mittels in form von mikrokapseln zur schabenbekaempfung. | |
| DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
| DE60136826D1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| ATE79720T1 (de) | Verfahren zur konservierung von transplantierbaren, in vitro kultivierten epithelgeweben. | |
| ATE222769T1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
| DE69940753D1 (de) | Verfahren zur Einführung von heterologischen Zellen in Fische | |
| DE69633393D1 (de) | Mitteln zur behandlung von auto-immun krankheiten | |
| ATE173620T1 (de) | Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs | |
| ATE371031T1 (de) | Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs | |
| ATE253117T1 (de) | Adenovirus e4 proteine für induktion von zelltod | |
| MXPA02005069A (es) | Agentes de enlace especificos para t3 y metodos para su uso. | |
| DE69432517D1 (de) | Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit | |
| BR9305035A (pt) | Agentes de curtimento e sua aplicaçáo | |
| DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
| DE3769497D1 (de) | Mittel zur bekaempfung von phytopathogenen mikroben. | |
| ES8801624A1 (es) | Procedimiento para preparar disulfuros heterociclicos | |
| DE69433851D1 (de) | Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |